Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The increasingly popular nicotine pouches pose a lower risk of cancer than cigarettes, U.S. health officials said.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

The FDA approved 50 novel drugs that contained an active ingredient not previously approved by the agency, whilst the EMA authorised 46 new medicines. Whilst racking up 50 novel drug approvals ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Marketing for the popular nicotine pouch product, Zyn, has been approved by the U.S. Food and Drug Administration to help ...